Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MMP3 | P08254 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.41 |
| ▸ | MMP10 | P09238 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12655999 | 0.87 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1MEN1KMT2AHCRTR1 | |
| SCHEMBL12623952 | 0.84 | L3MBTL1 (0.63) | L3MBTL1ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL15426435 | 0.84 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1MMP3MMP9MMP8 | |
| SCHEMBL12627182 | 0.83 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL12621946 | 0.82 | L3MBTL1 (0.61) | L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL15423912 | 0.81 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1MEN1KMT2AHCRTR1 | |
| SCHEMBL15427209 | 0.81 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1MEN1KMT2A | |
| SCHEMBL12623976 | 0.81 | ALDH1A1 (0.49) | L3MBTL1ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL12673214 | 0.80 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1HCRTR1HCRTR2 | |
| SCHEMBL12623988 | 0.80 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11385221-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| WO-2022098700-A1 | INHIBITING AN IMMUNE RESPONSE MEDIATED BY ONE OR MORE OF TLR2, RAGE, CCR5, CXCR4 AND CD4 | CASSAVA SCIENCES, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20210389298-A1 | Alzheimer's Disease Assay in a Living Patient | PAIN THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS, INC. | 2021-04-01 | — | — | US | disclosed |
| EP-3791875-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | Pain Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | Cassava Science, Inc. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3054956-B1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20190271686-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | PAIN THERAPEUTICS, INC. | 2019-09-05 | — | — | US | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| WO-2014012054-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATENT | PAIN THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20140017699-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140017699-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20110105487-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105487-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105481-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| US-20110105481-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS | 2011-05-05 | — | — | US | disclosed |
| WO-2010051497-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS, INC. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105487-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, FPR1 | L3MBTL1 4055/4885ALDH1A1 3041/4885MMP3 2063/4885 |
| US-10760052-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | L3MBTL1 1789/4885ALDH1A1 4388/4885MMP3 4460/4885 |
| US-20110105481-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, OPRK1 | L3MBTL1 3291/4885ALDH1A1 2575/4885MMP3 2181/4885 |
| US-20210095248-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | L3MBTL1 1789/4885ALDH1A1 4388/4885MMP3 4460/4885 |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | L3MBTL1 1789/4885ALDH1A1 4388/4885MMP3 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.